GSK shares jump on $2.2 billion Zantac settlement
Settlement resolves 80,000 or 93% of pending US cases
GSK top gainer on FTSE-100, best one-day gain since Dec 2022
To record 1.8 billion pounds charge in Q3 results
Rewrites paragraphs 1-3, adds investor comment in 4-5
By Maggie Fick and Yamini Kalia
Oct 10 (Reuters) -GSK GSK.L shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
The deal, announced on Wednesday, was far lower than many analysts and investors had expected, including JP Morgan's projection of $3.5 billion. Barclays analysts described it as a "best case scenario in terms of aggregate settlement".
The deal resolves 80,000, or 93%, of the pending cases against the company in the United States. Analysts at Jefferies and elsewhere said the news removed most of the overhang on the stock from the issue, which has dogged GSK for over two years.
"The settlement of $2.2 billion is lower than market expectations of $3.5 billion, and the announcement came sooner than expected. The Zantac clouds are lifting, and GSK will likely resolve the few remaining cases quickly," said Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares.
"Importantly, its core earnings are unaffected so investors can now focus on GSK delivering on its late-stage pipeline", Coutts told Reuters.
Concerns about lawsuits and potential compensation wiped almost $40 billion off the combined market values of GSK, Sanofi SASY.PA, Pfizer PFE.N and Haleon HLN.L, which all also sold the drug, over roughly a week in August 2022.
GSK shares were the top gainers on the FTSE benchmark .FTSE index on Thursday and on track for their best one-day percentage gain since December 2022.
The company will also pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory.
GSK admitted no wrongdoing or liability in the settlements, and said they were in the best long-term interest of the company to avoid the risk of continuing litigation.
The company expects to record a 1.8 billion pound ($2.4 billion) charge in its third quarter results due to the settlements, with no impact seen on its investment plans.
It will announce third quarter results on Oct. 30.
First approved by U.S. regulators in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim.
Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could degrade into NDMA, a carcinogen, over time or when exposed to heat. The recall triggered a spate of lawsuits.
($1 = 0.7642 pounds)
Reporting by Yamini Kalia in Bengaluru; Editing by Sharon Singleton and Mark Potter
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
